Living Donor Navigator Program Tele-health for Kidney Diseases
Phase-Based Progress Estimates
Effectiveness
Safety
University of Alabama at Birmingham, Birmingham, AL
Kidney Diseases
Living Donor Navigator Program - BehavioralEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
We hypothesize that expansion of the Living Donor Navigator (LDN) program to include tele-health delivery will overcome geographic disparities in access and facilitate sustained increases in living donation. We will utilize an individually randomized group trial (IRGT) design with delayed intervention initiation to compare the effectiveness of tele-health LDN model to standard of care.
Treatment Effectiveness
Effectiveness Progress
Other trials for Kidney Diseases
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Within 3 months of condition
Month 3
Number Live Donor Screenings
Number of Live Donor Approvals
Trial Safety
Safety Progress
Other trials for Kidney Diseases
Trial Design
2 Treatment Groups
Living Donor Navigator Program Tele-health
1 of 2
Living Donor Navigator Program In-person
1 of 2
Active Control
440 Total Participants · 2 Treatment Groups
Primary Treatment: Living Donor Navigator Program Tele-health · No Placebo Group · N/A
Living Donor Navigator Program Tele-health
Behavioral
ActiveComparator Group · 1 Intervention: Living Donor Navigator Program · Intervention Types: BehavioralLiving Donor Navigator Program In-person
Behavioral
ActiveComparator Group · 1 Intervention: Living Donor Navigator Program · Intervention Types: BehavioralTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 3 months of condition
Trial Background
Prof. Jayme E Locke, Professor of Surgery
Principal Investigator
University of Alabama at Birmingham
Closest Location: University of Alabama at Birmingham · Birmingham, AL
1991First Recorded Clinical Trial
21 TrialsResearching Kidney Diseases
1066 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have end-stage kidney disease (ESKD) and are ≥ 18 years old.
If there is an individual willing to donate, but the candidate is unwilling to consider this option or this particular individual, the candidate is eligible for the study and may still benefit from identification of new donors or increased comfort accepting donation from others.
You are fluent in English or deaf and hard of hearing.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments